Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

16 results for "Cancer" and "Endocrine Cancers" and "Lung"

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Protocol No
NRG-BN012
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors

This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
Protocol No
MABSPACE-TST001-1001
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-l

Phase 1/2 open-label, multicenter study to evaluate the safety, PK, and pharmacodynamics of HPN328 in patients with SCLC or with advanced solid tumors associated with expression of DLL3. This study will be divided into 2 parts: Dose Escalation (Part 1) and Expansion (Part 2).
Protocol No
HARPOON-HPN328-4001
Sub Category
Early Phase/Multiple Disease Site Cancers, Thoracic Cancers

A Phase I Study of GNX102 in Patients with Advanced Solid Tumors

This new medicine, GNX102, is an antibody that binds to a certain target on the surface of the cancer cells and may kill the cancer cells.

The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
Protocol No
GLYCONEX-GNX-001
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Gynecologic Cancers

Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectab

To assess the safety and tolerability of ociperlimab in combination with tislelizumab in
patients with advanced solid tumors. Then to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of ociperlimab in combination with tislelizumab, and determine the recommended Phase 2 dose (RP2D) of ociperlimab in combination with
tislelizumab.
Protocol No
BEIGENE-BGB-900-105
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Ma

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Sub Category
Gynecologic Cancers, Prostate and Urologic Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers